Literature DB >> 15454235

Small molecule inhibitors of the CCR2b receptor. Part 1: Discovery and optimization of homopiperazine derivatives.

Minoru Imai1, Tatsuki Shiota, Ken-ichiro Kataoka, Christine M Tarby, Wilna J Moree, Takaharu Tsutsumi, Masaki Sudo, Michele M Ramirez-Weinhouse, Daniel Comer, Chung-Ming Sun, Shinsuke Yamagami, Hiroko Tanaka, Takuya Morita, Takahiko Hada, Jonathan Greene, Doug Barnum, John Saunders, Peter L Myers, Yoshinori Kato, Noriaki Endo.   

Abstract

N,N'-Disubstituted homopiperazine derivatives have been discovered as CC-chemokine receptor 2b (CCR2b) inhibitors with submicromolar activity in the CCR2b binding assay. A 4-substituted benzyl group on one homopiperazine nitrogen was an important moiety for binding affinity to the CCR2b receptor. The SAR for CCR2b binding affinity correlated inversely with the sigma factor of the functional group on this benzyl moiety. Introduction of hydroxy groups to appropriate positions in the 3,3-diphenylpropyl group on the other homopiperazine nitrogen increased CCR2b binding activity. The synthesis of an informer library to search for alternative substructures is also described.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454235     DOI: 10.1016/j.bmcl.2004.08.008

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Targeted delivery of CCR2 antagonist to activated pulmonary endothelium prevents metastasis.

Authors:  Marko Roblek; Manuela Calin; Martin Schlesinger; Daniela Stan; Reiner Zeisig; Maya Simionescu; Gerd Bendas; Lubor Borsig
Journal:  J Control Release       Date:  2015-10-30       Impact factor: 9.776

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.